COMP <GO>
AKBA vs RNAC // ALTMAN Z-SCORE & DEBT/EQUITY
Akebia Therapeutics Inc. (NASDAQ) VS. Cartesian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AKBA 6
— RNAC 1
■ METRIC PARITY
LAST: $0.71 (+0.27%) • MKT CAP: $195.8M
balance-sheet
0.20
LAST: $6.34 (-2.31%) • MKT CAP: $196.4M
balance-sheet
0.20
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AKBA VS. RNAC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AKBA | RNAC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -35.00% | +120.00 | AKBA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 9.90% | -60.00% | +69.90 | AKBA | /operating-margins <GO> |
| Net Profit Margin | -2.20% | -60.00% | +57.80 | AKBA | /net-margins <GO> |
| Revenue Growth (YoY) | 47.50% | -65.00% | +112.50 | AKBA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 2/9 | +5.00 | AKBA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 42.9 | +2.30 | AKBA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $195.8M | $196.4M | -$581.7K | RNAC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AKBA REV | RNAC REV | AKBA GROSS % | RNAC GROSS % | AKBA FCF | RNAC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $236.2M | $400.0K | 83.3% | — | $67.7M | -$79.4M |
| FY 2024 | $160.2M | $38.3M | 60.6% | — | -$40.7M | -$32.8M |
| FY 2023 | $194.6M | $26.0M | — | — | -$23.4M | -$51.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AKBA // BETA —
RNAC // BETA —